Samsung Biologics (KRX: 207940) is the Korean contract development and manufacturing organization that has grown from a monoclonal antibody specialist into a multi-modality CDMO with a stated strategy to sit alongside Bachem, PolyPeptide, and CordenPharma at the top of the peptide capacity table. Headquartered in Incheon, the company operates one of the largest single-site biologics manufacturing footprints in the world and reported record revenue in fiscal year 2025.
The entry into peptides is the July 20, 2026 announcement of an all-cash public tender offer to acquire 100% of Swiss peptide CDMO PolyPeptide Group AG at CHF 44.31 per share (CHF 1.46 billion / approximately $1.8 billion, a 40% premium). Draupnir Holding B.V. (approximately 55.65% of PolyPeptide) committed to tender its shares, and PolyPeptide's independent board unanimously recommended the offer. On Monday August 31, 2026, Samsung Biologics (through its Swiss subsidiary Samsung Peptide AG) published the formal tender offer prospectus on SIX Swiss Exchange, triggering the 10 trading-day cooling-off period from September 1; the main offer period runs September 15 through October 12, 2026 at 4 p.m. Swiss time. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals; transaction close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites with the Incheon multi-modality footprint.
Stories here cover the PolyPeptide tender progress, Samsung's multi-modality strategy, capacity build-outs, and customer wins across mAbs, ADCs, and peptide APIs. See [[polypeptide-group]], [[peptide-cdmo-consolidation]], and [[bachem]] for adjacent threads.
The tender main offer period opened Tuesday September 15, 2026, and runs through October 12, 2026 at 4 p.m. CET. Draupnir Holding B.V.'s tender commitment covers the 55.65% baseline, and the incremental tenders needed to hit the 66⅔% threshold will come from institutional and retail free-float holders over the four-week window. If the threshold clears, Samsung intends to squeeze out remaining minorities and delist PolyPeptide from SIX Swiss Exchange, targeting an end-of-2026 close.
Samsung Biologics (KRX: 207940), through its direct Swiss subsidiary Samsung Peptide AG, opened Tuesday September 15, 2026 the main offer period for its public tender for all publicly held registered shares of PolyPeptide Group AG (SIX: PPGN). Terms: CHF 44.31 net in cash per PolyPeptide share, implied aggregate equity value of approximately CHF 1.46 billion (approximately $1.8 billion at prevailing FX). The main offer period runs September 15 through October 12, 2026 at 4:00 p.m. Central European Time. Closing conditions: 66⅔% minimum acceptance threshold on a fully diluted share count (excluding treasury shares), plus customary regulatory approvals. Draupnir Holding B.V. — PolyPeptide's largest single shareholder with approximately 55.65% of outstanding shares — has committed to tender all of its shares. PolyPeptide's independent directors unanimously recommend acceptance based on an independent fairness opinion from IFBC AG. The price represents a 40% premium to the April 10, 2026 closing price and an 11.6% premium to the 60-day volume-weighted average price prior to the July 20 pre-announcement. Transaction close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide, folding the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into Samsung's Incheon multi-modality footprint. The transaction consolidates one of the top three global peptide CDMO capacity positions alongside Bachem and CordenPharma.
The Samsung Biologics tender offer for PolyPeptide Group AG (announced July 20 at CHF 44.31 per share, CHF 1.46 billion / $1.8 billion, 40% premium) continued through Sunday September 6, 2026 in the 10 SIX Swiss Exchange trading-day cooling-off period that began September 1 following Samsung Peptide AG's August 31 publication of the formal tender offer prospectus. Under Swiss takeover law, the main offer period commences Tuesday September 15, 2026 and runs through October 12, 2026 at 4 p.m. Swiss time. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares outstanding) has committed to tender all of its shares. Transaction close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into Samsung's Incheon multi-modality footprint. The transaction will consolidate one of the top three global peptide CDMO capacity positions alongside Bachem and CordenPharma.
The Samsung Biologics tender offer for PolyPeptide Group AG (announced July 20 at CHF 44.31 per share, CHF 1.46 billion / $1.8 billion) entered its 10 SIX Swiss Exchange trading-day cooling-off period Tuesday September 1, 2026 following the Monday August 31 publication of the formal tender offer prospectus by Samsung's Swiss subsidiary Samsung Peptide AG. The main offer period commences Tuesday September 15 and runs through October 12, 2026 at 4 p.m. Swiss time. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares outstanding) has already committed to tender all of its shares. Transaction close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide from SIX, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into Samsung's Incheon multi-modality footprint alongside the existing monoclonal antibody and antibody-drug conjugate operations.
Samsung Biologics (KRX: 207940), through its Swiss subsidiary Samsung Peptide AG, published Monday August 31, 2026 the formal tender offer prospectus for all publicly held registered shares of PolyPeptide Group AG (SIX: PPGN) on SIX Swiss Exchange. Terms: CHF 44.31 net in cash per share (implied equity value approximately CHF 1.46 billion / $1.8 billion, a 40% premium to the CHF 31.65 undisturbed share price of April 10, 2026). The cooling-off period runs 10 SIX trading days from September 1, and the main offer period commences September 15, 2026 through October 12, 2026 at 4 p.m. Swiss time. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares) has committed to tender all shares. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals; transaction close is targeted for end of 2026. Samsung intends to squeeze out remaining minorities and delist PolyPeptide post-close, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into the Incheon multi-modality biologics footprint.
Peptide CDMO announced investments have crossed $2.4 billion year-to-date in 2026, driven primarily by GLP-1 demand and a broadening pipeline of therapeutic peptides beyond the incretin class. Anchor programs: Samsung Biologics' CHF 1.46 billion / $1.8 billion all-cash tender offer for PolyPeptide Group AG (tender prospectus targeted for end-of-August publication, offer period September 15 to October 12); Bachem's more than CHF 500 million Sisslerfeld greenfield site collaboration in Switzerland (commercial production 2030) plus the recent Building K commercial GMP ramp; CordenPharma's confirmed $500 million Boulder expansion to 42,000+ liters by 2028 plus greater-than-€500 million greenfield near Basel; AmbioPharm's US-based supply scaling; and Lonza's SPPS capacity extensions. The global peptide CDMO market reached $4.59 billion in 2025 and is projected to reach $29.12 billion by 2035 (CAGR 20.3%) according to newly-published market research. The build-out is the binding upstream constraint on how much of the GLP-1, macrocyclic, and peptide-drug-conjugate pipeline reaches commercial scale.
Samsung Biologics' $1.8 billion (CHF 1.46 billion) all-cash tender offer for Swiss peptide CDMO PolyPeptide Group (SIX: PPGN) is scheduled to publish the formal offer prospectus by the end of August 2026, following the mandatory 10 trading-day cooling-off period under Swiss takeover law. Terms: CHF 44.31 per share (40% premium to the CHF 31.65 undisturbed price on April 10, 2026). The offer will run for a minimum of 20 trading days on SIX Swiss Exchange and is conditioned on at least 66⅔% of shares tendered on a fully diluted basis plus customary regulatory approvals. Deal close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide. The transaction would give Samsung Biologics one of the top three peptide CDMO capacity positions globally, integrated with Samsung's existing multi-modality biologics network across the U.S., Europe, and India.
Barclays' Head of US Biopharma Equity Research Emily Field told CNBC Monday August 24, 2026 that the biotech mergers and acquisitions (M&A) freeze is over. Key drivers cited: capital markets reopening (drug startup IPOs have raised roughly $6 billion year-to-date, more than the combined total of the prior four years by this point), large-cap pharma buyers committing to more deals following a multi-year period of caution, and fresh oncology data extending the sector's value proposition beyond the weight-loss drug narrative that dominated 2024-2025. The commentary follows a rapid acceleration of biotech M&A activity through August: Samsung Biologics' pending $1.8 billion PolyPeptide Group AG all-cash tender offer (formal prospectus expected end of August), BioMarin Pharmaceutical's Alesta Therapeutics acquisition for ALE1 program (August 21), Tolerance Bio's $260 million exclusive license from NeoImmuneTech for NT-I7 (efineptakin alfa, long-acting IL-7 fusion protein, August 20), LEO Pharma's dersimelagon (MC1R agonist) acquisition from Mitsubishi Tanabe (August 18), and Hanmi Pharm's up-to-$2.3 billion HM17321 UCN2 licensing to Genentech announced the same Monday. The pattern suggests the M&A environment is now supportive for both mid-cap platform buyers (Samsung Biologics, LEO Pharma, BioMarin) and mega-cap oncology and metabolic-disease buyers (Roche/Genentech, Bristol Myers Squibb, Merck, Eli Lilly) actively pursuing deals. Field's commentary also notes that oncology data (particularly the Merck-Moderna intismeran Phase 3 melanoma win and Gilead Trodelvy+Keytruda EU authorization from the same week) has substantially reset investor expectations about the sector beyond obesity.
The broader peptide contract development and manufacturing organization (CDMO) consolidation wave continues across August 2026 with three concurrent developments. First, Samsung Biologics' pending $1.8 billion all-cash tender offer for PolyPeptide Group AG at CHF 44.31 per share (CHF 1.46 billion total equity value, 40% premium to undisturbed share price) advances toward closing: the formal tender offer prospectus is expected to be published by end of August 2026 following Draupnir Holding B.V. (55.65% stake) commitment to tender and PolyPeptide's Board of Directors unanimous recommendation, with closing expected toward end of 2026. Second, Gland Pharma and Neuland Laboratories announced August 11, 2026 a long-term sterile API manufacturing partnership in Visakhapatnam, India, extending India's growing role as a peptide API manufacturing hub. Third, Bachem, CordenPharma, and AmbioPharm continue capacity build-outs. Collective capacity positioning targets the multi-billion-dollar demand wave from semaglutide and tirzepatide commercial-scale API (roughly $17 billion combined active pharmaceutical ingredient market by 2028 per industry estimates) plus retatrutide, amycretin, VK2735, ribupatide, and next-generation combination peptide Phase 3 programs. The consolidation trajectory suggests peptide CDMO capacity concentration among a smaller number of large operators through the end of the decade, with the Samsung acquisition of PolyPeptide as the anchor transaction.
Samsung Biologics' all-cash tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share (CHF 1.46 billion / $1.8 billion, representing a 40% premium to the undisturbed share price of CHF 31.65) continues to progress. The formal tender offer prospectus is expected to be published by end of August 2026 and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange following a ten trading-day cooling-off period under Swiss takeover law. PolyPeptide's largest individual shareholder Draupnir Holding B.V. (owning approximately 55.65% of shares outstanding) has committed to tender all of its shares into the offer. PolyPeptide's independent Board of Directors unanimously recommends that shareholders accept Samsung Biologics' offer. The transaction would substantially expand Samsung Biologics' peptide CDMO manufacturing footprint beyond its existing antibody and antibody-drug conjugate focus, positioning the combined entity to address the rapidly growing peptide therapeutics demand particularly in obesity and diabetes GLP-1 therapies (Novo Nordisk Wegovy and Ozempic, Eli Lilly Zepbound and Mounjaro), amylin analogs (cagrilintide), and next-generation combination peptide drugs. PolyPeptide operates commercial-scale peptide API manufacturing across the US, Europe, and India. Closing is expected towards the end of 2026 subject to a minimum acceptance threshold of 66⅔% and applicable regulatory approvals.
Samsung Biologics announced Sunday-Monday July 19-20, 2026 an all-cash public tender offer to acquire Switzerland's PolyPeptide Group for CHF 1.46 billion ($1.8 billion) at CHF 44.31 per share, a 40% premium to the undisturbed share price of CHF 31.65. The transaction represents the largest biopharmaceutical M&A in South Korean history. Strategic rationale: PolyPeptide is a global peptide contract development and manufacturing organization (CDMO) with accelerating revenue growth driven by rising client demand for peptide-based GLP-1 therapies for obesity and diabetes. The acquisition expands Samsung Biologics' capabilities beyond monoclonal antibody manufacturing (its historical strength) into peptide therapeutics and adds PolyPeptide's global network spanning Sweden, Belgium, France, the United States, and India, encompassing R&D, development, and commercial manufacturing capabilities. PolyPeptide's Board of Directors unanimously recommends the offer. The largest shareholder has given an irrevocable tender undertaking representing approximately 55.65% of outstanding shares. Samsung Biologics expects to complete the deal by end of 2026. The deal extends the July 2026 peptide-manufacturing consolidation wave alongside Novartis's $1.5 billion Myricx Bio acquisition (ADC payloads, July 6) and Lonza's Nona Biosciences TfR1 blood-brain-barrier deal (July 2).